-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga·10/29/2026 12:05:42
Listen to the news

Gainers

  • Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion.
  • Glaukos (NYSE:GKOS) stock rose 15.75% to $210.01. The company's market cap stands at $10.7 billion. As per the press release, Q3 earnings came out yesterday.
  • Teladoc Health (NYSE:TDOC) stock rose 13.37% to $7.8. The company's market cap stands at $1.2 billion. The company's, Q3 earnings came out yesterday.
  • Insmed (NASDAQ:INSM) stock increased by 12.39% to $109.0. The company's market cap stands at $21.1 billion. As per the news, the Q3 earnings report came out today.
  • Hyperliquid Strategies (NASDAQ:PURR) shares moved upwards by 10.83% to $11.05. The market value of their outstanding shares is at $1.9 billion.
  • Vanda Pharmaceuticals (NASDAQ:VNDA) stock rose 8.71% to $4.35. The company's market cap stands at $240.5 million. As per the press release, Q3 earnings came out yesterday.

Losers

  • Iovance Biotherapeutics (NASDAQ:IOVA) shares decreased by 25.9% to $10.98 during Thursday's pre-market session. The company's market cap stands at $6.6 billion.
  • Community Health System (NYSE:CYH) stock fell 14.29% to $2.28. The market value of their outstanding shares is at $375.0 million. As per the news, the Q3 earnings report came out yesterday.
  • Haleon (NYSE:HLN) stock decreased by 14.2% to $8.58. The market value of their outstanding shares is at $43.9 billion.
  • DBV Technologies (NASDAQ:DBVT) shares decreased by 10.71% to $9.51. The market value of their outstanding shares is at $669.3 million. The company's, Q3 earnings came out yesterday.
  • Lakewood-Amedex (NASDAQ:LABT) shares fell 10.18% to $0.26.
  • Coherus Oncology (NASDAQ:CHRS) stock decreased by 9.92% to $1.04. The company's market cap stands at $179.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.